Hepatitis C Incidence- a Comparison Between Injection and Noninjection Drug Users in New York City
dc.contributor.author | Fuller, Crystal M. | en_US |
dc.contributor.author | Ompad, Danielle C. | en_US |
dc.contributor.author | Galea, Sandro | en_US |
dc.contributor.author | Wu, Yingfeng | en_US |
dc.contributor.author | Koblin, Beryl | en_US |
dc.contributor.author | Vlahov, David | en_US |
dc.date.accessioned | 2006-07-27T18:57:47Z | |
dc.date.available | 2006-07-27T18:57:47Z | |
dc.date.issued | 2004 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/40369 | |
dc.description.abstract | Hepatitis C virus (HCV) burdens injection drug users (IDUs) with prevalence estimated from 60–100% compared to around 5% among noninjection drug users (non-IDUs). We present preliminary data comparing the risk for HCV among IDUs and non-IDUs to inform new avenues of HCV prevention and intervention planning. Two cohorts, new IDUs (injecting≤ 3 years) and non-IDUs (smoke/sniff heroine, crack or cocaine≤ 10 years), ages 15–40, were street-recruited in New York City. Participants underwent risk surveys and HCV serology at baseline and 6-month follow-up visits. Person-time analysis was used to estimate annual HCV incidence. Of 683 non-IDUs, 653 were HCV seronegative, 422 returned for at least 1 follow-up visit, and 1 became HCV seropositive. Non-IDUs contributed 246.3 person-years (PY) yielding an annual incident rate of 0.4/100 PY (95% Confidence Interval [CI]=0.0-1.2). Of 260 IDUs, 114 were HCV seronegative, 62 returned for at least 1 follow-up visit, and 13 became HCV seropositive. IDUs contributed 36.3 PY yielding an annual incidence rate of 35.9/100 PY (95%CI=19.1–61.2). Among IDUs, HCV seroconverters tended to be younger (median age 25 vs. 28, respectively), and inject more frequently (61.5% vs. 34.7%, respectively) than nonseroconverters. These interim data suggest that IDUs may have engaged in high-risk practices prior to being identified for prevention services. Preventing or at least delaying transition into injection could increase opportunity to intervene. Identifying risk factors for transition into injection could inform early prevention to reduce onset of injection and risk of HCV. | en_US |
dc.format.extent | 1931 bytes | |
dc.format.extent | 68613 bytes | |
dc.format.mimetype | text/plain | |
dc.format.mimetype | application/pdf | |
dc.language.iso | en_US | en_US |
dc.title | Hepatitis C Incidence- a Comparison Between Injection and Noninjection Drug Users in New York City | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | |
dc.contributor.affiliationum | Epidemiology, Department of | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/40369/2/Fuller_Hepatitis C Incidence - a Comparison Betwwen Injection_2004.pdf | en_US |
dc.owningcollname | Epidemiology, Department of (SPH) |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.